Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Viridian Therapeutics, Inc.\DE (VRDN) over the last 8 years, with Q3 2025 value amounting to $102000.0.

  • Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges rose 4166.67% to $102000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $367000.0, marking a year-over-year decrease of 1678.0%. This contributed to the annual value of $377000.0 for FY2024, which is 1892.74% up from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges stood at $102000.0, which was up 4166.67% from $103000.0 recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges peaked at $128000.0 during Q4 2022, and registered a low of $49000.0 during Q3 2022.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges had a median value of $87000.0 in 2021 and averaged $87800.0.
  • The largest annual percentage gain for Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges in the last 5 years was 13207.55% (2024), contrasted with its biggest fall of 5203.25% (2024).
  • Viridian Therapeutics, Inc.\DE's Amortization of Deferred Charges (Quarter) stood at $87000.0 in 2021, then surged by 47.13% to $128000.0 in 2022, then decreased by 3.91% to $123000.0 in 2023, then crashed by 52.03% to $59000.0 in 2024, then soared by 72.88% to $102000.0 in 2025.
  • Its Amortization of Deferred Charges was $102000.0 in Q3 2025, compared to $103000.0 in Q2 2025 and $103000.0 in Q1 2025.